Skip to main content
SpringerLink
Log in

Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents: Prevalence, Efficacy, Risks and Research Needs

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Polypharmacy, defined as the concomitant use of two or more psychotropic drugs, has become increasingly common in the paediatric and adolescent population over the past two decades. Combining psychotropic drugs leads to possible increases in benefits, but also in risks, particularly given the potential for psychotropic drug interactions. Despite the increasing use of concomitant therapy in children and adolescents, there is very little evidence from controlled clinical trials to provide guidance for prescribers. Even while acknowledging the small evidence base, clinical practice guidelines from eminent medical organizations are either relatively silent on or tend to support the use of concomitant treatments more enthusiastically than the evidence would warrant, so that practice and guidance are running ahead of the science. Our narrative review shows that the published evidence for efficacy and safety of concomitant psychotropic drugs in children and adolescents is scanty. A comprehensive search located 37 studies published over the last decade, of which 18 were randomized controlled trials (RCTs). These focused mainly on stimulants, central sympatholytics (such as clonidine), antipsychotics and ‘mood stabilizers’. While several small, often methodologically weak, RCTs demonstrated statistically significant advantages for dual pharmacotherapy over monotherapy, only adding central sympatholytics to stimulants for treating attention-deficit hyperactivity disorder (ADHD) symptoms was supported by substantial studies with an effect size large enough to suggest clinical importance. Non-randomized studies tended to have results that supported concomitant treatment, but all have design-related problems that decrease the reliability of the results. Two studies that specifically examined tolerability of combination pharmacotherapy compared with monotherapy showed significant increases in adverse effects, both subjective and objective, and other studies confirmed a statistically significant increase in adverse effects, including sedation and self-harm. Given the extent of combination therapy occurring, particularly in conditions such as ADHD, and the ambiguous evidence for benefit with clear evidence of harm, we propose that further research should be carried out as a matter of urgency. Until such a time, the attitude to combination pharmacotherapy should be conservative, and combining psychotropic medications should be considered as an ‘n of 1’ trial to be closely monitored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6(6):695–704.

    Article  PubMed  Google Scholar 

  2. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry. 2010;49:1001–10.

    Article  PubMed  Google Scholar 

  3. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics. Eur Neuropsychopharmacol. 2009;19(7):520–32.

    Article  PubMed  CAS  Google Scholar 

  4. Joshi G, Gerogiopoulos AM. Combination pharmacotherapy for psychiatric disorders in children and adolescents. Rosenberg DR, Gershon S (eds) Pharmacotherapy of child and adolescent psychiatric disorders, chap. 17. 3rd ed. New York: Wiley; 2012.

  5. Pincus HA, Tew JD, First MB. Psychiatric comorbidity: is more less? World Psychiatry. 2004;3(1):18–23.

    PubMed  Google Scholar 

  6. Beddoe R. Dying for a cure. New York: Random House; 2007.

  7. Rashed AN, Wong ICK, Cranswick N, et al. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2011. doi:10.1007/s00228-011-1183-4.

  8. Kaminer Y, Goldberg P, Connor DF. Psychotropic medications and substances of abuse interactions in youth. Subst Abuse. 2010;31:53–7.

    Article  Google Scholar 

  9. Muscatello MR, Spina E, Bandelow B, Baldwin DS. Clinical relevant drug interactions in anxiety disorders. Human Psychopharmacol Clin Exp. 2012. doi:10.1002/hup.2217. Accessed 29 Mar 2012.

  10. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86:203–15.

    Article  PubMed  CAS  Google Scholar 

  11. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Therap. 2008;30(7):1206–27.

    Article  CAS  Google Scholar 

  12. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Safety. 2008;7:587–96.

    Article  CAS  Google Scholar 

  13. Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Safety. 2002;25:91–110.

    Article  PubMed  CAS  Google Scholar 

  14. Chen H, Patel A, Sherer J, et al. The definition and prevalence of pediatric psychotropic polypharmacy. Pyschiatric Serv. 2011;62:1450–5.

    Article  Google Scholar 

  15. McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. J Clin Psychiatry. 2009;70:240–6.

    Article  PubMed  Google Scholar 

  16. Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state medicaid program. Clin Therap. 2010;32(5):949–59.

    Article  Google Scholar 

  17. Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolescent Psychopharmacol. 2006;16(3):273–85.

    Article  Google Scholar 

  18. Griffith AK, Huscroft-D’Angelo J, Epstein MH, et al. Psychotropic medication use for youth in residential treatment: a comparison between youth with monopharmacy versus polypharmacy. J Child Fam Stud. 2010;19:795–802.

    Article  Google Scholar 

  19. Russell PSS, George C, Mammen P. Predictive factors for polypharmacy among child and adolescent psychiatry inpatients. Clin Pract Epidemiol Mental Health. 2006;2:25.

    Article  Google Scholar 

  20. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20:623–32.

    Article  PubMed  Google Scholar 

  21. Fontanella CA, Bridge JA, Campo JV. Psychotropic medication changes, polypharmacy and the risk of early readmission in suicidal adolescent inpatients. Ann Pharmacother. 2009;43:1939–47.

    Article  PubMed  Google Scholar 

  22. Zoega H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol. 2009;19:757–64.

    Article  PubMed  Google Scholar 

  23. Zito JM, Safer DJ, Jon-van den Berg LTW, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Mental Health. 2008;2:26.

    Article  Google Scholar 

  24. Gerhard T, Chavez B, Olfson M, et al. National patterns of the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol. 2009;29:307–10.

    Article  PubMed  Google Scholar 

  25. Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1):e157–63.

    Article  PubMed  Google Scholar 

  26. Duffy FF, Narrow WE, Rae DS, et al. Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol. 2005;15:12–25.

    Article  PubMed  Google Scholar 

  27. National Collaborating Centre for Mental Health. CG72 Attention deficit hyperactivity disorder (ADHD): full guideline. UK: The British Psychological Society and The Royal College of Psychiatrists; 2009. http://www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf.

  28. National Collaborating Centre for Mental Health. CG28 Depression in Children and Young People. Identification and management in primary, community and secondary care. UK: The British Psychological Society and The Royal College of Psychiatrists; 2005.

  29. Martin A, Scahill L, Kratochvil C. Pediatric psychopharmacology principles and practice. 2nd ed. Oxford: Oxford University of Press; 2011.

  30. Kutcher S, Chehil S. Physical treatments, Rutter’s child and adolescent psychiatry. 5th ed. New York: Blackwell Publishing Limited; 2008.

  31. Rosenberg D, Gershon S (eds) Pharmacotherapy of child and adolescent psychiatric disorders. 3rd ed. Chichester: John Wiley & Sons; 2012.

  32. George JN, Vesely SK, Woolf SH. Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods. Am J Med Qual. 2013;20:1–8.

    Google Scholar 

  33. AACAP. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48:9.

    Google Scholar 

  34. Findling RL, McNamara NK, Gracious BL, et al. Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry. 2003;42(8):895–901.

    Article  PubMed  Google Scholar 

  35. Steering committee on quality improvement and subcommittee on attention-deficit/hyperactivity disorder. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–22.

    Article  Google Scholar 

  36. Safer DJ, Zito JM, dosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160:438–49.

    Article  PubMed  Google Scholar 

  37. Gittelman-Klein R, Klein DF, Katz S, Saraf K, et al. Comparative effects of methylphenidate and thioridazine in hyperkinetic children, I: clinical results. Arch Gen Psychiatry. 1976;33:1217–31.

    Article  PubMed  CAS  Google Scholar 

  38. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr. 2000;39:15–25.

    Article  CAS  Google Scholar 

  39. Carlson GA, Rapport MD, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol. 1995;5:191–204.

    Article  Google Scholar 

  40. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1–37.

    Article  PubMed  Google Scholar 

  41. Palumbo DR, Sallee FR, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180–8.

    Article  PubMed  Google Scholar 

  42. Kurlan R, Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics. Neurology. 2002;58:527–36.

    Article  Google Scholar 

  43. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.

    Article  PubMed  Google Scholar 

  44. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–13.

    Article  PubMed  Google Scholar 

  45. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915–24.

    Article  PubMed  Google Scholar 

  46. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:5.

    Article  Google Scholar 

  47. Hazell P, Jairam R. Acute treatment of mania in children and adolescents. Curr Opin Psychiatry. 2012;25:264–70.

    Article  PubMed  Google Scholar 

  48. Cannon M, Pelham WH, Sallee R, CAT Study Team, et al. Effects of clonidine and methylphenidate on family quality of life in attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:511–7.

    Article  PubMed  Google Scholar 

  49. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886–94.

    Article  PubMed  Google Scholar 

  50. Perera H, Jeewandara KC, Seneviratne S, et al. ADHD refractory to methylphenidate treatment: a double-blind, placebo-controlled study combined Ω3 and Ω6 supplementation in children with attention-deficit hyperactivity disorder. J Child Neurol. 2012;27:747.

    Article  PubMed  Google Scholar 

  51. Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, et al. Acetyl-l-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev. 2011;42(3):367–75.

    Article  PubMed  Google Scholar 

  52. Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12):1392–401.

    Article  PubMed  Google Scholar 

  53. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558–65.

    Article  PubMed  Google Scholar 

  54. Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009;19(5):553–61.

    Article  PubMed  Google Scholar 

  55. Scheffer RE, Kowatch RA, Carmody TC, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilisation with divalproex sodium. Am J Psychiatry. 2005;162:58–64.

    Article  PubMed  Google Scholar 

  56. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4:9.

    Article  PubMed  Google Scholar 

  57. Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol. 2011;21(1):1–19.

    Article  PubMed  CAS  Google Scholar 

  58. Farmer CA, Arnold LE, Bukstein OG, Findling RL, et al. The treatment of severe child aggression (TOSCA) study: design challenges. Child Adolesc Psychiatry Ment Health. 2011;5(1):36.

    Article  PubMed  Google Scholar 

  59. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216–23.

    Article  PubMed  Google Scholar 

  60. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):32–6.

    Article  PubMed  CAS  Google Scholar 

  61. Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1269–72.

    Article  PubMed  CAS  Google Scholar 

  62. Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31(5):369–75.

    Article  PubMed  Google Scholar 

  63. Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501–10.

    Article  PubMed  Google Scholar 

  64. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215–26.

    Article  PubMed  Google Scholar 

  65. Wilens TE, Hammerness P, Utziner L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009;19(5):485–92.

    Article  PubMed  Google Scholar 

  66. Snyder R, Turgay A, Aman M, Risperidone Conduct Study Group, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatr. 2002;41(9):1026–36.

    Google Scholar 

  67. Aman MG, DeSmedt G, Derivan A, The Risperidone Disruptive Behavior Study Group, et al. Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159:1337–46.

    Article  PubMed  Google Scholar 

  68. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14(2):243–54.

    Article  PubMed  Google Scholar 

  69. Kronenberger WG, Giauque AL, Lafata DE, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334–47.

    Article  PubMed  Google Scholar 

  70. Chang K, Nayar D, Howe M, et al. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009;19(5):547–51.

    Article  PubMed  Google Scholar 

  71. Findling RL, McNamara NK, Stansbrey R, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom restabilisation. J Am Acad Child Adolesc Psychiatry. 2006;45(2):142–8.

    Article  PubMed  Google Scholar 

  72. Kafantaris V, Coletti DJ, Dicker R, et al. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatryr. 2001;40(12):1448–56.

    Article  CAS  Google Scholar 

  73. Kafantaris V, Dicker R, Coletti DJ, et al. Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J Child Adolesc Psychopharmacol. 2001;11(4):409–13.

    Article  PubMed  CAS  Google Scholar 

  74. Kowatch RA, Sethuraman G, Hume JH, Kromelis M, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 2003;53(11):978–84.

    Article  PubMed  CAS  Google Scholar 

  75. Pavuluri MN, Henry DB, Carbray JA, et al. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord. 2004;82(Suppl 1):S103–11.

    Article  PubMed  CAS  Google Scholar 

  76. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):298–304.

    Article  PubMed  Google Scholar 

  77. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574–9.

    Article  PubMed  Google Scholar 

  78. Shamseddeen W, Clarke G, Keller MB, et al. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012;22(1):29–36.

    Article  PubMed  CAS  Google Scholar 

  79. Kondo DG, Sung YH, Hellem TL, et al. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord. 2011;135(1–3):354–61.

    Article  PubMed  Google Scholar 

  80. Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19(5):539–45.

    Article  PubMed  Google Scholar 

  81. Hammerness P, Georgiopoulos A, Doyle R, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009;19(5):493–9.

    Article  PubMed  Google Scholar 

  82. Calarge CA, Acion L, Kuperman S, et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19(2):101–9.

    Article  PubMed  Google Scholar 

  83. Bahk WM, Shin YC, Woo JM, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prof Neuropsychopharmacol Biol Psychiatry. 2005;29(1):115–21.

    Article  CAS  Google Scholar 

  84. Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther. 2012;29(5):385–400.

    Article  PubMed  CAS  Google Scholar 

  85. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19(5):563–73.

    Article  PubMed  Google Scholar 

  86. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;41(1):65–73.

    Article  Google Scholar 

  87. Safer D. Age-grouped differences in adverse drug events from psychotropic medication. J Child Adolesc Psychopharmacol. 2004;21(4):299–309.

    Article  Google Scholar 

  88. Jureidini J. Key opinion leaders in psychiatry: a conflicted pathway to career advancement. Aust N Z J Psychiatry. 2012;46:495–7.

    Article  PubMed  Google Scholar 

  89. Cutting edge information. Key opinion leaders (PH122) relationship management and segmentation data. 2009 Extracts. http://www.cuttingedgeinfo.com/research/medical-affairs/key-opinion-leaders/. Accessed Feb 2012 (Full copy available from Jon Jureidini).

  90. Allen S. Backlash on bipolar diagnoses in children: MGH psychiatrist’s work stirs debate. Boston Globe June 17, 2007. http://www.boston.com/yourlife/health/diseases/articles/2007/06/17/backlash_on_bipolar_diagnoses_in_children/.

  91. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank anonymous reviewers for careful analysis of earlier drafts of this paper.

No sources of funding were used to assist with the preparation of the review.

Conflicts of interest

Jon Jureidini, Anne Tonkin and Elsa Jureidini do not have any dualities of interest to declare. Jon Jureidini and Elsa Jureidini are members of Healthy Skepticism, an organisation that aims to counter misleading drug promotion.

Author information

Authors and Affiliations

  1. Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia

    Jon Jureidini

  2. Medicine Learning and Teaching Unit, School of Medicine, University of Adelaide, Adelaide, SA, Australia

    Anne Tonkin

  3. Sydney Local Health District, Camperdown, Australia

    Elsa Jureidini

  4. Department of Psychological Medicine, Women’s and Children’s Hospital, North Adelaide, SA, 5006, Australia

    Jon Jureidini

Authors
  1. Jon Jureidini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Tonkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elsa Jureidini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jon Jureidini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jureidini, J., Tonkin, A. & Jureidini, E. Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents: Prevalence, Efficacy, Risks and Research Needs. Pediatr Drugs 15, 377–391 (2013). https://doi.org/10.1007/s40272-013-0032-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-013-0032-6

Keywords

Search

Navigation